|
Nov 9
|
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
|
|
Nov 8
|
ChromaDex Corp (CDXC) Reports Growth in Net Sales and Positive Adjusted EBITDA in Q3 2023
|
|
Nov 8
|
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
|
|
Nov 1
|
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
|
|
Oct 31
|
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
|
|
Sep 3
|
Insider Stock Buying Reaches US$1.3m On ChromaDex
|
|
Jul 18
|
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
|